Should You Buy Biogen Before a Big July Decision?
19/3 10:30
Over time, Biogen (NASDAQ: BIIB) created a true success story. The biotech company built up an impressive portfolio of multiple sclerosis (MS) drugs and generated billions of dollars in earnings. The share price followed, climbing more than 20,000% from its initial public offerin...